Methylphenidate vs. resperidone in treatment of methamphetamine dependence: A clinical trial

Solhi, Hassan; Jamilian, Hamidreza; Kazemifar, Amir Mohammad; Javaheri, Javad; Barzaki, Akram Rasti

doi:10.1016/j.jsps.2013.04.003

Cited by 6 publications

(5 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results were in accordance with some previous studies [ 32 , 41 , 42 ]. Tiihonen and his colleagues have compared methylphenidate with aripiprazol for treatment of methamphetamine dependence, however, their study ended prematurely due to unexpected results of interim analysis and all of their patients were intravenous drug abuser; yet their results have been promising.…”

Section: Discussionsupporting

confidence: 94%

Sustained-release methylphenidate in methamphetamine dependence treatment: a double-blind and placebo-controlled trial

et al. 2015

View full text Add to dashboard Cite

BackgroundThe objective of this randomized, double-blind, placebo-controlled study was to evaluate the efficacy of sustained-release methylphenidate (MPH-SR) in treatment of methamphetamine dependence.MethodsFifty-six individuals who met DSM-IV-TR criteria for methamphetamine dependence participated in this 10-week trial. The participants were randomly allocated into two groups and received 18 to 54 mg/day sustained-released methylphenidate or placebo for 10 weeks. Craving was evaluated by a visual analogue craving scale every week. Urinary screening test for methamphetamine was carried out each week. The Beck Depression Inventory-II (BDI-II) was used to monitor participant depressive symptoms at baseline and bi-weekly during the treatment period.ResultsAt the end of the trial, the MPH-SR group was less methamphetamine positive compared to the placebo group and the difference was significant (p = 0.03). By the end of the study, MPH-SR group showed significantly less craving scores compared to the placebo group [MD (95% CI) = -10.28(0.88-19.18), t(54) = 2.19, p = 0.03]. There was greater improvement in the depressive symptoms scores in the intervention group compared to the placebo group [MD (95% CI) =2.03(0.31-3.75), t (54) =2.37, p = 0.02].ConclusionSustained-released methylphenidate was safe and well tolerated among active methamphetamine users and significantly reduced methamphetamine use, craving and depressive symptoms.Trial registrationIRCT201202281556N38

show abstract

Section: Discussionsupporting

confidence: 94%

Sustained-release methylphenidate in methamphetamine dependence treatment: a double-blind and placebo-controlled trial

et al. 2015

View full text Add to dashboard Cite

show abstract

“…In third trial the self-reported days of PWUM [ 55 ], but not in a fourth study [ 20 ]. In has been shown that the MPH at 10 mg/day is able to decrease the craving symptoms less than risperidone [ 19 ]. The primary pharmacologic effect of MPH is to enhance nor-epinephrine activity and dopamine, which impacts reward system function.…”

Section: Discussionmentioning

confidence: 99%

“…Tiihonen et al [ 18 ] showed the administration of 54 mg/day MPH compared with aripiprazole to patients with severe amphetamine dependence for 20 weeks led to a significant fewer amphetamine positive urine. Also, evidence studies have demonstrated that both risperidone and MPH can be useful for treatment of PWUM, in order to decrease the drug craving and somatic, psychological, and neurologic problems [ 19 ]. However, in another study, MPH administration was associated with no changes in the percentage of positive urines [ 20 ].…”

Section: Introductionmentioning

confidence: 99%

The therapeutic effects of methylphenidate and matrix-methylphenidate on addiction severity, craving, relapse and mental health in the methamphetamine use disorder

Aryan

Banafshe

Farnia

et al. 2020

Subst Abuse Treat Prev Policy

View full text Add to dashboard Cite

Background Little evidence has examined the therapeutic effects of methylphenidate (MPH) and Matrix Model treatment on addiction severity, craving, relapse and mental health in people who use methamphetamine (PWUM). This study was conducted to determine the effects of MPH, Matrix Model treatment, and Matrix-MPH on addiction severity, craving, relapse and mental health in PWUM. Methods This clinical trial was conducted among 100 patients with METH users. Participants were randomly divided into four groups who received: 1) 22 sessions of 45-min, twice a week for Matrix Model treatment (n = 25); 2) MPH 10 mg/day in the first month, 7.5 mg/day in the second month and 5 mg/day in the third month (n = 25); 3) Matrix Model treatment combined with MPH (n = 25); 4) control group (n = 25) for 12 weeks. Addiction severity, craving, relapse and mental status were evaluated at baseline and end-of-trial. Results Matrix Model treatment combined with MPH significantly reduced MA craving (P < 0.001) and addiction severity (P < 0.001). In addition, Matrix Model treatment combined with MPH resulted in a significant increase of mental health (P = 0.001), compared with Matrix Model treatment, MPH, and control group. Also, negative METH urine test significantly increased in the Matrix Model treatment combined with MPH group compared with the other groups (P < 0.001). Conclusions In conclusion, Matrix Model treatment combined with MPH for 12 weeks had beneficial effects on addiction severity, craving, relapse, and mental health in PWUM, compared with Matrix Model treatment, MPH, and control group. Trial registration This study was retrospectively registered in the Iranian website (www.irct.ir) for clinical trials registration (http://www.irct.ir: IRCT20171105037245N1). Registration date: 9 December 2017.

show abstract

“…Our search yielded 20 results, 11 of which did not meet inclusion criteria for this review [ 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 ]. Nine studies, including 242 participants met inclusion criteria (Figure 1 ).…”

Section: Resultsmentioning

confidence: 99%

Pharmacological treatment for methamphetamine withdrawal: A systematic review and meta‐analysis of randomised controlled trials

Acheson

Williams

Farrell

et al. 2022

Drug and Alcohol Review

View full text Add to dashboard Cite

Issues Cessation of methamphetamine use may result in a characteristic withdrawal syndrome, no medication has been approved for this indication. This systematic review aims to assess the efficacy of pharmacotherapy for methamphetamine withdrawal, the first comprehensive meta‐analysis since 2008. Approach MEDLINE (1966–2020), CINAHL (1982–2020), PsychINFO (1806–2020) and EMBASE (1947–2020) were systematically searched. Studies were included if they were randomised controlled trials (RCT) investigating pharmacological treatments for methamphetamine withdrawal, reviewing outcomes of treatment discontinuation, mental health outcomes, withdrawal symptoms (including craving) and patient safety. The relative risk (RR) and weighted mean difference (MD) were used to meta‐analyse dichotomous and continuous data respectively, with 95% confidence intervals. Risk of bias and Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) assessments were conducted. Key Findings Nine RCTs of six medications (n = 242 participants) met inclusion criteria, however, only six trials of four medications (n = 186) could be meta‐analysed. Mean sample size across studies was 27 participants, and 88% of participants were male. The quality of evidence in this review varies from low to very low on GRADE assessments. Amineptine may reduce discontinuation rates (RR 0.22, 95% confidence interval [CI] 0.07, 0.72, p = 0.01), and improve global state (MD −0.49, 95% CI −0.80, −0.17), compared with placebo, however, this medication is no longer approved. No other medications improved any domain when compared with placebo. Due to lack of reporting safety profiles could not be established. Conclusions There is insufficient evidence to indicate any medication is effective for the treatment of methamphetamine withdrawal. The poor quality of the evidence indicates a need for better powered, high‐quality trials.

show abstract

Methylphenidate vs. resperidone in treatment of methamphetamine dependence: A clinical trial

Cited by 6 publications

References 15 publications

Sustained-release methylphenidate in methamphetamine dependence treatment: a double-blind and placebo-controlled trial

Sustained-release methylphenidate in methamphetamine dependence treatment: a double-blind and placebo-controlled trial

The therapeutic effects of methylphenidate and matrix-methylphenidate on addiction severity, craving, relapse and mental health in the methamphetamine use disorder

Pharmacological treatment for methamphetamine withdrawal: A systematic review and meta‐analysis of randomised controlled trials

Contact Info

Product

Resources

About